Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-59f8fd8595-klmmf Total loading time: 0 Render date: 2023-03-21T14:13:03.883Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

Chapter 17 - Pharmacological Cosmetic Neurology

Published online by Cambridge University Press:  30 November 2019

By
Erin C. Conrad  and
Anjan Chatterjee
Edited by
Kenneth M. Heilman  and
Stephen E. Nadeau
Kenneth M. Heilman
Affiliation:
University of Florida
Stephen E. Nadeau
Affiliation:
University of Florida
Get access

Summary

“Cosmetic neurology,” also referred to as “cognitive enhancement,” is the practice of enhancing cognition and behavior in healthy people. Although cosmetic neurology often refers to the enhancement of cognition, it can also refer to the enhancement of mood, movement, creativity, social finesse, and other psychological attributes. Cosmetic neurology carries the promise of an improved quality of life and productivity well into old age, as well as potential medical and social perils. In this chapter, we review our understanding of the efficacy of drugs including stimulants and cholinesterase inhibitors that can be used for enhancement. We review their potential benefits to the individual and society. We also place the practice of cosmetic neurology in the context of current cultural norms and outline ethical concerns that this practice generates.

Keywords

pharmacologyenhancementneuroethicsstimulantscognition
Type
Chapter
Information
Cognitive Changes and the Aging Brain , pp. 264 - 277
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Purchase

Buy Book

Buy print or eBook[Opens in a new window]

References

Chatterjee, A. Cosmetic neurology: the controversy over enhancing movement, mentation, and mood. Neurology. 2004;63(6):968–74.CrossRefGoogle Scholar
Chatterjee, A. Cosmetic neurology and cosmetic surgery: parallels, predictions, and challenges. Camb Q Healthc Ethics. 2007;16(2):129–37.CrossRefGoogle ScholarPubMed
Haiken, E. Venus Envy: A History of Cosmetic Surgery. Baltimore: Johns Hopkins University Press; 1997.Google Scholar
Snelders, S, Pieters, T. Speed in the Third Reich: metamphetamine (Pervitin) use and a drug history from below. Soc Hist Med. 2011;24(3):686–99.CrossRefGoogle Scholar
Vearrier, D, Greenberg, MI, Miller, SN, Okaneku, JT, Haggerty, DA. Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine. Disease-a-Month. 2012 Feb;58(2):38–89.CrossRefGoogle ScholarPubMed
Steinkamp, P. Pervitin (methamphetamine) tests, use and misuse in the German Wehrmacht. In: Eckart, WU, editor. Man, Medicine, and the State: The Human Body as an Object of Government Sponsored Medical Research in the 20th Century. Stuttgart: Steiner; 2006, pp. 61–71.Google Scholar
Husain, M, Mehta, MA. Cognitive enhancement by drugs in health and disease. Trends Cogn Sci. 2011 Jan;15(1):28–36.CrossRefGoogle ScholarPubMed
Sostek, AJ, Buchsbaum, MS, Rapoport, JL. Effects of amphetamine on vigilance performance in normal and hyperactive children. J Abnorm Child Psychol. 1980 Dec;8(4):491–500.CrossRefGoogle ScholarPubMed
Koelega, HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology. 1993;111(1):1–16.CrossRefGoogle ScholarPubMed
Pigeau, R, Naitoh, P, Buguet, A, McCann, C, Baranski, J, Taylor, M, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res. 1995;4(4):212–28.CrossRefGoogle ScholarPubMed
Baranski, JV, Pigeau, R, Dinich, P, Jacobs, I. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharm Clin. 2004 Jul;19(5):323–32.CrossRefGoogle ScholarPubMed
Elliott, R, Sahakian, BJ, Matthews, K, Bannerjea, A, Rimmer, J, Robbins, TW. Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology. 1997 May;131(2):196–206.CrossRefGoogle ScholarPubMed
Bagot, KS, Kaminer, Y. Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: a systematic review. Addiction. 2014 Apr;109(4):547–57.CrossRefGoogle ScholarPubMed
Breitenstein, C, Wailke, S, Bushuven, S, Kamping, S, Zwitserlood, P, Ringelstein, EB, et al. D-amphetamine boosts language learning independent of its cardiovascular and motor arousing effects. Neuropsychopharmacology. 2004 Sep;29(9):1704–14.CrossRefGoogle ScholarPubMed
Repantis, D, Schlattmann, P, Laisney, O, Heuser, I. Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010 Sep;62(3):187–206.CrossRefGoogle ScholarPubMed
Franke, AG, Gränsmark, P, Agricola, A, Schühle, K, Rommel, T, Sebastian, A, et al. Methylphenidate, modafinil, and caffeine for cognitive enhancement in chess: a double-blind, randomised controlled trial. Eur Neuropsychopharmacol. 2017 Mar;27(3):248–60.CrossRefGoogle ScholarPubMed
Franke, AG, Lieb, K. Pharmacological neuroenhancement: substances and epidemiology. In: Hildt, E, Franke, AG, editors. Cognitive Enhancement: An Interdisciplinary Perspective. Dordrecht: Springer Netherlands; 2013, pp. 17–27.CrossRefGoogle Scholar
Fond, G, Micoulaud-Franchi, J-A, Brunel, L, Macgregor, A, Miot, S, Lopez, R, et al. Innovative mechanisms of action for pharmaceutical cognitive enhancement: a systematic review. Psychiatry Res. 2015;229(1):12–20.CrossRefGoogle ScholarPubMed
Winblad, B, Engedal, K, Soininen, H, Verhey, F, Waldemar, G, Wimo, A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 Aug 14;57(3):489–95.CrossRefGoogle ScholarPubMed
Wesnes, KA, McKeith, IG, Ferrara, R, Emre, M, Del Ser, T, Spano, PF, et al. Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord. 2002;13(3):183–92.CrossRefGoogle Scholar
Rowan, E, McKeith, IG, Saxby, BK, O’Brien, JT, Burn, D, Mosimann, U, et al. Effects of donepezil on central processing speed and attentional measures in Parkinson’s disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2007;23(3):161–7.CrossRefGoogle ScholarPubMed
Ferreira-Vieira, TH, Guimaraes, IM, Silva, FR, Ribeiro, FM. Alzheimer’s disease: targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):101–15.CrossRefGoogle ScholarPubMed
Repantis, D, Laisney, O, Heuser, I. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res. 2010 Jun;61(6):473–81.CrossRefGoogle ScholarPubMed
FitzGerald, DB, Crucian, GP, Mielke, JB, Shenal, BV, Burks, D, Womack, KB, et al. Effects of donepezil on verbal memory after semantic processing in healthy older adults. Cogn Behav Neurol. 2008 Jun;21(2):57–64.CrossRefGoogle ScholarPubMed
Yesavage, JA, Mumenthaler, MS, Taylor, JL, Friedman, L, O’Hara, R, Sheikh, J, et al. Donepezil and flight simulator performance: effects on retention of complex skills. Neurology. 2002 Jul 9;59(1):123–5.CrossRefGoogle ScholarPubMed
Chuah, LYM, Chee, MWL. Cholinergic augmentation modulates visual task performance in sleep-deprived young adults. J Neurosci. 2008 Oct 29;28(44):11369–77.CrossRefGoogle ScholarPubMed
Chuah, LYM, Chong, DL, Chen, AK, Rekshan, WR 3rd, Tan, J-C, Zheng, H, et al. Donepezil improves episodic memory in young individuals vulnerable to the effects of sleep deprivation. Sleep. 2009 Aug;32(8):999–1010.CrossRefGoogle ScholarPubMed
Reisberg, B, Doody, R, Stöffler, A, Schmitt, F, Ferris, S, Möbius, HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003 Apr 3;348(14):1333–41.CrossRefGoogle ScholarPubMed
Rammsayer, TH. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem. 2001;8(1):20–5.CrossRefGoogle ScholarPubMed
Watfa, G, Rossignol, P, Kearney-Schwartz, A, Fay, R, Bracard, S, Felblinger, J, et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens. 2010 Dec;28(12):2485–93.CrossRefGoogle ScholarPubMed
Rose, SPR. “Smart drugs”: do they work? Are they ethical? Will they be legal? Nat Rev Neurosci. 2002 Dec;3(12):975–9.CrossRefGoogle Scholar
Ng, TP, Feng, L, Yap, KB, Lee, TS, Tan, CH, Winblad, B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis. 2014;41(1):61–8.CrossRefGoogle ScholarPubMed
Luchsinger, JA, Ma, Y, Christophi, CA, Florez, H, Golden, SH, Hazuda, H, et al. Metformin, lifestyle intervention, and cognition in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2017 Jul;40(7):958–65.CrossRefGoogle ScholarPubMed
Solomon, PR, Adams, F, Silver, A, Zimmer, J, DeVeaux, R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002 Aug 21;288(7):835–40.CrossRefGoogle ScholarPubMed
Birks, J, Grimley, Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007;2:CD003120.Google Scholar
Calabrese, C, Gregory, WL, Leo, M, Kraemer, D, Bone, K, Oken, B. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008 Jul;14(6):707–13.CrossRefGoogle ScholarPubMed
Flicker, L, Evans, JG. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;2:CD001011.Google Scholar
Ng, T-P, Chiam, P-C, Lee, T, Chua, H-C, Lim, L, Kua, E-H. Curry consumption and cognitive function in the elderly. Am J Epidemiol. 2006 Nov 1;164(9):898–906.CrossRefGoogle ScholarPubMed
Solon, O. Meet the Silicon Valley-ites taking tiny hits of LSD to boost performance. Wired. 2016 Aug 24.
Johnstad, PG. Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordic Studies on Alcohol and Drugs. 2018;35(1):39–51.CrossRefGoogle Scholar
Franke, AG, Bagusat, C, Rust, S, Engel, A, Lieb, K. Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci. 2014 Nov;264(Suppl 1):S83–S90.CrossRefGoogle ScholarPubMed
Singh, I, Bard, I, Jackson, J. Robust resilience and substantial interest: a survey of pharmacological cognitive enhancement among university students in the UK and Ireland. PLoS ONE. 2014 Oct 30;9(10):e105969.CrossRefGoogle ScholarPubMed
Dietz, P, Striegel, H, Franke, AG, Lieb, K, Simon, P, Ulrich, R. Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy. 2013 Jan;33(1):44–50.CrossRefGoogle ScholarPubMed
Babcock, Q, Byrne, T. Student perceptions of methylphenidate abuse at a public liberal arts college. J Am Coll Health. 2000 Nov;49(3):143–5.CrossRefGoogle Scholar
McCabe, SE, Knight, JR, Teter, CJ, Wechsler, H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005 Jan;100(1):96–106.CrossRefGoogle ScholarPubMed
Arria, AM, O’Grady, KE, Caldeira, KM, Vincent, KB, Wish, ED. Nonmedical use of prescription stimulants and analgesics: associations with social and academic behaviors among college students. J Drug Issues. 2008;38(4):1045–60.CrossRefGoogle ScholarPubMed
Arria, AM, Wilcox, HC, Caldeira, KM, Vincent, KB, Garnier-Dykstra, LM, O’Grady, KE. Dispelling the myth of “smart drugs”: cannabis and alcohol use problems predict nonmedical use of prescription stimulants for studying. Addict Behav. 2013 Mar;38(3):1643–50.CrossRefGoogle ScholarPubMed
Emanuel, RM, Frellsen, SL, Kashima, KJ, Sanguino, SM, Sierles, FS, Lazarus, CJ. Cognitive enhancement drug use among future physicians: findings from a multi-institutional census of medical students. J Gen Intern Med. 2013 Aug;28(8):1028–34.CrossRefGoogle ScholarPubMed
Franke, AG, Bagusat, C, Dietz, P, Hoffmann, I, Simon, P, Ulrich, R, et al. Use of illicit and prescription drugs for cognitive or mood enhancement among surgeons. BMC Med. 2013 Apr 9;11(1):102.CrossRefGoogle ScholarPubMed
Caballero, J, Ownby, RL, Rey, JA, Clauson, KA. Cognitive and performance enhancing medication use to improve performance in poker. J Gambl Stud. 2016 Sep;32(3):835–45.CrossRefGoogle ScholarPubMed
Dietz, P, Soyka, M, Franke, AG. Pharmacological neuroenhancement in the field of economics – poll results from an online survey. Front Psychol. 2016 Apr 19;7:520.CrossRefGoogle ScholarPubMed
Franke, AG, Heinrich, I, Lieb, K, Fellgiebel, A. The use of Ginkgo biloba in healthy elderly. Age. 2014;36(1):435–44.CrossRefGoogle ScholarPubMed
Arria, AM, Caldeira, KM, Vincent, KB, O’Grady, KE, Cimini, MD, Geisner, IM, et al. Do college students improve their grades by using prescription stimulants nonmedically? Addict Behav. 2017 Feb;65:245–9.CrossRefGoogle ScholarPubMed
Baranski, JV, Pigeau, RA. Self-monitoring cognitive performance during sleep deprivation: effects of modafinil, d-amphetamine and placebo. J Sleep Res. 1997 Jun;6(2):84–91.CrossRefGoogle ScholarPubMed
Sharp, C. Cognitive enhancers – performance or problem? Occup Med. 2016 Mar;66(2):88–9.CrossRefGoogle ScholarPubMed
Dekkers, W, Rikkert, MO. Memory enhancing drugs and Alzheimer’s disease: enhancing the self or preventing the loss of it? Med Health Care Philos. 2007;10(2):141–51.CrossRefGoogle ScholarPubMed
Arce, E, Ehlers, MD. The mind bending quest for cognitive enhancers. Clinical Pharmacology & Therapeutics. 2017;101(2):179–81.CrossRefGoogle ScholarPubMed
Brand, R, Wolff, W, Ziegler, M. Drugs as instruments: describing and testing a behavioral approach to the study of neuroenhancement. Front Psychol. 2016 Aug 17;7:1226.CrossRefGoogle Scholar
Chatterjee, A. Framing pains, pills, and professors. Expositions. 2008;2(2):139–46.Google Scholar
Brignell, CM, Rosenthal, J, Curran, HV. Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. J Psychopharmacol. 2007 Sep;21(7):673–83.CrossRefGoogle ScholarPubMed
Pitman, RK, Sanders, KM, Zusman, RM, Healy, AR, Cheema, F, Lasko, NB, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry. 2002 Jan 15;51(2):189–92.CrossRefGoogle ScholarPubMed
Clewis, RR. Does Kantian ethics condone mood and cognitive enhancement? Neuroethics. 2017;10(3):349–61.CrossRefGoogle Scholar
Schaefer, GO, Kahane, G, Savulescu, J. Autonomy and enhancement. Neuroethics. 2014;7(2):123–36.CrossRefGoogle ScholarPubMed
Harada, CN, Love, MCN, Triebel, KL. Normal cognitive aging. Clin Geriatr Med. 2013 Nov;29(4):737–52.CrossRefGoogle ScholarPubMed
English, V, Sommerville, A. Boosting Your Brainpower, Ethical Aspects of Cognitive Enhancements: A Discussion Paper. London: British Medical Association; 2007.Google Scholar
Lucke, J, Partridge, B. Towards a smart population: a public health framework for cognitive enhancement. Neuroethics. 2013;6(2):419–27.CrossRefGoogle Scholar
Maslen, H, Santoni de Sio, F, Faber, N. With cognitive enhancement comes great responsibility? In: Koops, B-J, Oosterlaken, I, Romijn, H, Swierstra, T, van den Hoven, J, editors. Responsible Innovation 2. Cham: Switzerland: Springer International Publishing; 2015, pp. 121–38.Google Scholar
Batéjat, DM, Lagarde, DP. Naps and modafinil as countermeasures for the effects of sleep deprivation on cognitive performance. Aviat Space Environ Med. 1999 May;70(5):493–8.Google ScholarPubMed
Lerner, BH. A case that shook medicine. Washington Post. 2006 Nov 28.
Lerner, BH. A life-changing case for doctors in training. New York Times. 2009 Mar 3.
Chandler, JA, Dodek, AM. Cognitive enhancement in the courtroom. In: Jotterand, F, Dubljevic, V, editors. Cognitive Enhancement: Ethical and Policy Implications in International Perspectives. New York: Oxford University Press; 2016, pp. 329–45.CrossRefGoogle Scholar
Grunstein, RR, Banerjee, D. The case of “Judge Nodd” and other sleeping judges – media, society, and judicial sleepiness. Sleep. 2007;30(5):625–32.CrossRefGoogle ScholarPubMed
Danziger, S, Levav, J, Avnaim-Pesso, L. Extraneous factors in judicial decisions. Proc Natl Acad Sci. 2011 Apr 26;108(17):6889–92.CrossRefGoogle ScholarPubMed
Weinshall-Margel, K, Shapard, J. Overlooked factors in the analysis of parole decisions. Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):E833.CrossRefGoogle ScholarPubMed
Rachlinski, JJ, Johnson, SL, Wistrich, AJ, Guthrie, C. Does unconscious bias affect trial judges? Notre Dame Law Review. 2009;84(3):1195–246.Google Scholar
Persson, I, Savulescu, J. The perils of cognitive enhancement and the urgent imperative to enhance the moral character of humanity. J Appl Philos. 2008;25(3):162–77.CrossRefGoogle Scholar
Hoffman, P. The Man Who Loved Only Numbers: The Story of Paul Erdos and the Search for Mathematical Truth. New York: Hyperion; 1998.Google Scholar
Carter, S. Could moral enhancement interventions be medically indicated? Health Care Anal. 2017 Dec;25(4):338–53.CrossRefGoogle ScholarPubMed
Douglas, T. Moral enhancement. J Appl Philos. 2008 Aug;25(3):228–45.CrossRefGoogle ScholarPubMed
Shook, JR. Neuroethics and the possible types of moral enhancement. AJOB Neurosci. 2012;3(4):3–14.CrossRefGoogle Scholar
Ahlskog, R. Moral enhancement should target self-interest and cognitive capacity. Neuroethics. 2017 Apr 26;10(3):363–73.CrossRefGoogle ScholarPubMed
Harris, J. Moral enhancement and freedom. Bioethics. 2010;25(2):102–11.Google ScholarPubMed
Kirsch, I. The Emperor’s New Drugs: Exploding the Antidepressant Myth. New York: Basic Books; 2009.Google Scholar
Rutherford, BR, Mori, S, Sneed, JR, Pimontel, MA, Roose, SP. Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. J Psychiatr Res. 2012 Jun;46(6):697–702.CrossRefGoogle ScholarPubMed
Benedetti, F. Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol. 2008;48:33–60.CrossRefGoogle ScholarPubMed
Ilieva, I, Boland, J, Farah, MJ. Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people. Neuropharmacology. 2013 Jan;64:496–505.CrossRefGoogle ScholarPubMed
Ioannidis, JPA. Why most published research findings are false. PLoS Med. 2005 Aug;2(8):e124.CrossRefGoogle ScholarPubMed
Button, KS, Ioannidis, JPA, Mokrysz, C, Nosek, BA, Flint, J, Robinson, ESJ, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013 May;14(5):365–76.Google ScholarPubMed
Wilens, TE, Hammerness, PG, Biederman, J, Kwon, A, Spencer, TJ, Clark, S, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005 Feb;66(2):253–9.CrossRefGoogle ScholarPubMed
Nissen, SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445–8.CrossRefGoogle ScholarPubMed
Habel, LA, Cooper, WO, Sox, CM, Arnold Chan, K, Fireman, BH, Arbogast, PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–83.CrossRefGoogle Scholar
Cooper, WO, Habel, LA, Sox, CM, Arnold Chan, K, Arbogast, PG, Craig Cheetham, T, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365(20):1896–904.CrossRefGoogle ScholarPubMed
Busardò, FP, Kyriakou, C, Cipolloni, L, Zaami, S, Frati, P. From clinical application to cognitive enhancement: the example of methylphenidate. Curr Neuropharmacol. 2016;14(1):17–27.CrossRefGoogle ScholarPubMed
Biederman, J, Monuteaux, MC, Spencer, T, Wilens, TE, Macpherson, HA, Faraone, SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008 May;165(5):597–603.CrossRefGoogle ScholarPubMed
Barkley, RA, Fischer, M, Smallish, L, Fletcher, K. Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics. 2003 Jan;111(1):97–109.CrossRefGoogle ScholarPubMed
Brühl, AB, Sahakian, BJ. Drugs, games, and devices for enhancing cognition: implications for work and society. Ann N Y Acad Sci. 2016 Apr;1369(1):195–217.CrossRefGoogle ScholarPubMed
Banjo, OC, Nadler, R, Reiner, PB. Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS ONE. 2010 Dec 14;5(12):e14322.CrossRefGoogle ScholarPubMed
Partridge, BJ, Bell, SK, Lucke, JC, Yeates, S, Hall, WD. Smart drugs “as common as coffee”: media hype about neuroenhancement. PLoS ONE. 2011 Nov 30;6(11):e28416.CrossRefGoogle ScholarPubMed
Schermer, M. Changes in the self: the need for conceptual research next to empirical research. Am J Bioeth. 2009 May;9(5):45–7.CrossRefGoogle ScholarPubMed
Shanker, T, Duenwald, M. Threats and responses: military; bombing error puts a spotlight on pilots’ pills. New York Times. 2003 Jan 19.
Schermer, M, Bolt, I, de Jongh, R, Olivier, B. The future of psychopharmacological enhancements: expectations and policies. Neuroethics. 2009;2(2):75–87.CrossRefGoogle Scholar
Davis, NJ. A taxonomy of harms inherent in cognitive enhancement. Front Hum Neurosci. 2017 Feb 14;11. ArtID: 63.Google Scholar
Heilman, KM, Nadeau, SE, Beversdorf, DO. Creative innovation: possible brain mechanisms. Neurocase. 2003 Oct;9(5):369–79.CrossRefGoogle ScholarPubMed
Beversdorf, DQ, Hughes, JD, Steinberg, BA, Lewis, LD, Heilman, KM. Noradrenergic modulation of cognitive flexibility in problem solving. Neuroreport. 1999 Sep 9;10(13):2763–7.CrossRefGoogle ScholarPubMed
Farah, MJ, Haimm, C, Sankoorikal, G, Smith, ME, Chatterjee, A. When we enhance cognition with Adderall, do we sacrifice creativity? A preliminary study. Psychopharmacology. 2009 Jan;202(1–3):541–7.CrossRefGoogle ScholarPubMed
Fukuyama, F. Our Posthuman Future: Consequences of the Biotechnology Revolution. New York: Farrar, Straus and Giroux; 2002.Google Scholar
Daniels, N. Normal functioning and the treatment-enhancement distinction. Camb Q Healthc Ethics. 2000 Summer;9(3):309–22.CrossRefGoogle ScholarPubMed
Reiner, PB. Distinguishing between restoration and enhancement in neuropharmacology. Virtual Mentor. 2010 Nov 1;12(11):885–8.Google ScholarPubMed
Caviola, L, Faber, NS. Pills or push-ups? Effectiveness and public perception of pharmacological and non-pharmacological cognitive enhancement. Front Psychol. 2015;6:1852.CrossRefGoogle ScholarPubMed
Scheske, C, Schnall, S. The ethics of “smart drugs”: moral judgments about healthy people’s use of cognitive-enhancing drugs. Basic Appl Soc Psych. 2012;34(6):508–15.CrossRefGoogle Scholar
Specker, J, Schermer, MHN, Reiner, PB. Public attitudes towards moral enhancement. Evidence that means matter morally. Neuroethics. 2017 Jul 27;10(3):405–17.CrossRefGoogle ScholarPubMed
Bergström, LS, Lynöe, N. Enhancing concentration, mood and memory in healthy individuals: an empirical study of attitudes among general practitioners and the general population. Scand J Public Health. 2008 Jul;36(5):532–7.CrossRefGoogle ScholarPubMed
Kudlow, PA, Naylor, KT, Xie, B, McIntyre, RS. Cognitive enhancement in Canadian medical students. J Psychoactive Drugs. 2013 Sep;45(4):360–5.CrossRefGoogle ScholarPubMed
Greely, H, Sahakian, B, Harris, J, Kessler, RC, Gazzaniga, M, Campbell, P, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature. 2008;456(7223):702–5.CrossRefGoogle ScholarPubMed
Bostrom, N, Sandberg, A. Cognitive enhancement: methods, ethics, regulatory challenges. Sci Eng Ethics. 2009 Sep;15(3):311–41.CrossRefGoogle Scholar
Kass, LR. Ageless bodies, happy souls: biotechnology and the pursuit of perfection. The New Atlantis. 2003 Spring;1(1):9–28.Google Scholar
President’s Council on Bioethics (U.S.), Kass, L. Beyond Therapy: Biotechnology and the Pursuit of Happiness. New York: Harper Perennial; 2003.Google Scholar
Elliot, C. American bioscience meets the American dream. Am Prospect. 2003;14(6):38.Google Scholar
Appel, JM. When the boss turns pusher: a proposal for employee protections in the age of cosmetic neurology. J Med Ethics. 2008 Aug;34(8):616–18.CrossRefGoogle ScholarPubMed
Enck, GG. Pharmaceutical enhancement and medical professionals. Med Health Care Philos. 2014 Feb;17(1):23–8.CrossRefGoogle ScholarPubMed
Ray, KS. Not just “study drugs” for the rich: stimulants as moral tools for creating opportunities for socially disadvantaged students. Am J Bioeth. 2016;16(6):29–38.CrossRefGoogle ScholarPubMed
Graf, WD, Nagel, SK, Epstein, LG, Miller, G, Nass, R, Larriviere, D. Pediatric neuroenhancement: ethical, legal, social, and neurodevelopmental implications. Neurology. 2013 Mar 26;80(13):1251–60.CrossRefGoogle ScholarPubMed
Cakic, V. Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology. J Med Ethics. 2009 Oct;35(10):611–15.CrossRefGoogle ScholarPubMed
Klayman, A. Take Your Pills. Netflix; 2018.Google Scholar
Sattler, S, Sauer, C, Mehlkop, G, Graeff, P. The rationale for consuming cognitive enhancement drugs in university students and teachers. PLoS ONE. 2013 Jul 17;8(7):e68821.CrossRefGoogle ScholarPubMed
Lucke, J, Partridge, B, Forlini, C, Racine, E. Using neuropharmaceuticals for cognitive enhancement: policy and regulatory issues. In: Clausen, J, Levy, N, editors. Handbook of Neuroethics. Dordrecht: Springer Netherlands; 2014, pp. 1085–100.Google Scholar
Shook, JR, Galvagni, L, Giordano, J. Cognitive enhancement kept within contexts: neuroethics and informed public policy. Front Syst Neurosci. 2014 Dec 5;8:228.CrossRefGoogle ScholarPubMed
Synofzik, M. Ethically justified, clinically applicable criteria for physician decision-making in psychopharmacological enhancement. Neuroethics. 2009;2(2):89–102.CrossRefGoogle Scholar
Bostrom, N. Drugs can be used to treat more than disease. Nature. 2008;451(7178):520.CrossRefGoogle ScholarPubMed
Ravelingien, A, Braeckman, J, Crevits, L, De Ridder, D, Mortier, E. “Cosmetic neurology” and the moral complicity argument. Neuroethics. 2009;2(3):151–62.CrossRefGoogle Scholar
Ott, R, Lenk, C, Miller, N, Neuhaus Bühler, R, Biller-Andorno, N. Neuroenhancement – perspectives of Swiss psychiatrists and general practitioners. Swiss Med Wkly. 2012 Nov 27;142:w13707.Google ScholarPubMed
Hotze, TD, Shah, K, Anderson, EE, Wynia, MK. “Doctor, would you prescribe a pill to help me … ?” a national survey of physicians on using medicine for human enhancement. Am J Bioeth. 2011 Jan;11(1):3–13.CrossRefGoogle ScholarPubMed
Outram, SM, Racine, E. Developing public health approaches to cognitive enhancement: an analysis of current reports. Public Health Ethics. 2011;4(1):93–105.CrossRefGoogle Scholar
Heinz, A, Kipke, R, Heimann, H, Wiesing, U. Cognitive neuroenhancement: false assumptions in the ethical debate. J Med Ethics. 2012 Jun;38(6):372–5.CrossRefGoogle ScholarPubMed
Zohny, H. The myth of cognitive enhancement drugs. Neuroethics. 2015;8(3):257–69.CrossRefGoogle Scholar
Schelle, KJ, Faulmüller, N, Caviola, L, Hewstone, M. Attitudes toward pharmacological cognitive enhancement – a review. Front Syst Neurosci. 2014 Apr 17;8:53.CrossRefGoogle ScholarPubMed
Bell, S, Partridge, B, Lucke, J, Hall, W. Australian university students’ attitudes towards the acceptability and regulation of pharmaceuticals to improve academic performance. Neuroethics. 2013;6(1):197–205.CrossRefGoogle Scholar
Aikins, RD. Academic performance enhancement: a qualitative study of the perceptions and habits of prescription stimulant–using college students. J Coll Stud Dev. 2011;52(5):560–76.CrossRefGoogle Scholar
Desantis, AD, Hane, AC. “Adderall is definitely not a drug”: justifications for the illegal use of ADHD stimulants. Subst Use Misuse. 2010;45(1–2):31–46.CrossRefGoogle Scholar
Dodge, T, Williams, KJ, Marzell, M, Turrisi, R. Judging cheaters: is substance misuse viewed similarly in the athletic and academic domains? Psychol Addict Behav. 2012 Sep;26(3):678–82.CrossRefGoogle ScholarPubMed
Fitz, NS, Nadler, R, Manogaran, P, Chong, EWJ, Reiner, PB. Public attitudes toward cognitive enhancement. Neuroethics. 2014;7(2):173–88.CrossRefGoogle Scholar
Franke, AG, Bonertz, C, Christmann, M, Engeser, S, Lieb, K. Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: a pilot study. AJOB Prim Res. 2012;3(1):48–57.CrossRefGoogle Scholar
Franke, AG, Lieb, K, Hildt, E. What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement. PLoS ONE. 2012;7(6):e40047.CrossRefGoogle ScholarPubMed
Partridge, B, Bell, S, Lucke, J, Hall, W. Australian university students’ attitudes towards the use of prescription stimulants as cognitive enhancers: perceived patterns of use, efficacy and safety. Drug Alcohol Rev. 2013;32(3):295–302.CrossRefGoogle ScholarPubMed
Partridge, B, Lucke, J, Hall, W. A comparison of attitudes toward cognitive enhancement and legalized doping in sport in a community sample of Australian adults. AJOB Prim Res. 2012;3(4):81–6.CrossRefGoogle Scholar
Sabini, J, Monterosso, J. Judgments of the fairness of using performance enhancing drugs. Ethics Behav. 2005;15(1):81–94.CrossRefGoogle ScholarPubMed
Sattler, S, Forlini, C, Racine, É, Sauer, C. Impact of contextual factors and substance characteristics on perspectives toward cognitive enhancement. PLoS ONE. 2013;8(8):e71452.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×